Fenwarth Laurène (@laurenefenwarth) 's Twitter Profile
Fenwarth Laurène

@laurenefenwarth

#MyeloidNeoplasm, #CancerPredisposition, @CHU_Lille

ID: 1243475258927185920

calendar_today27-03-2020 09:49:46

9 Tweet

14 Takipçi

34 Takip Edilen

CHU de Lille (@chu_lille) 's Twitter Profile Photo

Une nouvelle piste pour comprendre les formes graves du Covid-19 👉 1 patient sur 2 atteint concerné par l'altération appelée hématopoïèse clonale 👏 bravo aux chercheurs lillois CHU et Canther_Lille pour cette 1ère mondiale #TaskForceCovidLille bit.ly/306mwxp

Une nouvelle piste pour comprendre les formes graves du Covid-19 
👉 1 patient sur 2 atteint concerné par l'altération appelée hématopoïèse clonale 
👏 bravo aux chercheurs lillois CHU et <a href="/Canther_Lille/">Canther_Lille</a> pour cette 1ère mondiale 
#TaskForceCovidLille
bit.ly/306mwxp
ASH (@ash_hematology) 's Twitter Profile Photo

Our clinical practice guidelines on acute myeloid leukemia in older adults are now published in Blood Advances! The guidelines help patients and health care providers make critical decisions, including if and how to proceed with treatment buff.ly/3kiOD4G #ASHGuidelines

Our clinical practice guidelines on acute myeloid leukemia in older adults are now published in <a href="/BloodAdvances/">Blood Advances</a>! The guidelines help patients and health care providers make critical decisions, including if and how to proceed with treatment buff.ly/3kiOD4G #ASHGuidelines
Blood Journal (@bloodjournal) 's Twitter Profile Photo

A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia ow.ly/Xyz550DqrZg #AML

A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia ow.ly/Xyz550DqrZg #AML
Elli Papaemmanuil, PhD (@papaemmanuillab) 's Twitter Profile Photo

It is clear. If there is one thing we owe to patients, hemato-oncologists, pathologists, clinical trialists, scientists & regulators is to unify the CAC/ICC & WHO classification ASAP. Why wait for the next revision? #ASH22 inspiration

It is clear. If there is one thing we owe to patients, hemato-oncologists, pathologists, clinical trialists, scientists &amp; regulators is to unify the CAC/ICC &amp; WHO classification ASAP. Why wait for the next revision? #ASH22 inspiration
Alexandra Gomez A. (@agomez_md) 's Twitter Profile Photo

Prognostic Impact of Monoallelic vs Biallelic TP53 in AML. Presented by Fenwarth Laurène . Biallelic TP53=2 mutations or 1 + either TP53 locus deletion or TP53 CN-LOH. Biallelic had worst 2yrOS(4 vs43%). Mono=similar OS as ELN int risk. ativsoftware.com/appinfo.php?pa… #ASH22

Prognostic Impact of Monoallelic vs Biallelic TP53 in AML. Presented by <a href="/LaureneFenwarth/">Fenwarth Laurène</a> . Biallelic TP53=2 mutations or 1 + either TP53 locus deletion or TP53 CN-LOH. Biallelic had worst 2yrOS(4 vs43%). Mono=similar OS as ELN int risk. 
ativsoftware.com/appinfo.php?pa…
#ASH22
Action Leucémies (@actionleucemies) 's Twitter Profile Photo

Le 43ème congrès de #sfh se déroulera du 29 au 31 mars 2023 au Palais des Congrès Porte Maillot RDV majeur des avancées scientifiques et médicales, Action Leucémies est fière d’y voir d’anciens lauréats de sa bourse de Recherche Mathieu Simonin, Laurène Fenwarth, Juliette Lambert

Le 43ème congrès de #sfh se déroulera du 29 au 31 mars 2023 au Palais des Congrès Porte Maillot
RDV majeur des avancées scientifiques et médicales, Action Leucémies est fière d’y voir d’anciens lauréats de sa bourse de Recherche Mathieu Simonin, Laurène Fenwarth, Juliette Lambert
Naveen Pemmaraju, MD (@doctorpemm) 's Twitter Profile Photo

👉👉👉Very important article just out from our group in Haematologica 📣 led by Dr .Guillaume Richard-Carpentier & Dr .Tapan Kadia ➡️ Characteristics & clinical outcomes of patients with AML with inv(3) or t(3;3) #leusm #endcancer MD Anderson Cancer Center Hagop Kantarjian,MD haematologica.org/article/view/h…

👉👉👉Very important article just out from our group in <a href="/Haematologica/">Haematologica</a> 📣 led by Dr .<a href="/grichardmd/">Guillaume Richard-Carpentier</a> &amp; Dr .<a href="/TapKadia/">Tapan Kadia</a> ➡️ Characteristics &amp; clinical outcomes of patients with AML with inv(3) or t(3;3) #leusm #endcancer <a href="/MDAndersonNews/">MD Anderson Cancer Center</a> <a href="/DrHKantarjian/">Hagop Kantarjian,MD</a> 

haematologica.org/article/view/h…